# CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

> **NCT07048353** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Shandong Qilu Cell Therapy Engineering Technology Co., Ltd** · enrollment: 15 (estimated)

## Conditions studied

- Lymphoma
- B Cell Lymphoma
- CD30+ Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** chimeric antigen receptor gene modified T cells

## Key facts

- **NCT ID:** NCT07048353
- **Lead sponsor:** Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2029-07-28
- **Final completion:** 2029-07-28
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07048353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07048353, "CD30 CAR-T in the Treatment of CD30 Positive Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07048353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*